Next Article in Journal
Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry and Network Pharmacology Reveal the Mechanisms of Rhodiola crenulata in Improving Non-Alcoholic Fatty Liver Disease
Previous Article in Journal
From Lineage to Longevity: A Field Guide to the Key Players in Epigenetic Contribution to Offspring Health
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 47
Issue 5
10.3390/cimb47050325
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Caprylic Acid Restores Branched-Chain Amino Acid Metabolism in a Mouse Cachexia Model

by
Isao Kawahara
1,2,
Rina Fujiwara-Tani
1,*,
Takuya Mori
1,3,
Shota Nukaga
1,2,
Ryoichi Nishida
1,
Yoshihiro Miyagawa
1,
Kei Goto
1,
Hitoshi Ohmori
1,
Kiyomu Fujii
1,
Yi Luo
1,
Takamitsu Sasaki
1,
Chie Nakashima
1,
Ruiko Ogata
1 and
Hiroki Kuniyasu
1,*
1
Department of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan
2
Division of Rehabilitation, Hanna Central Hospital, Ikoma 630-0243, Japan
3
Department of Medical Ethics and Genetics, Kyoto University, Kyoto 606-8501, Japan
*
Authors to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2025, 47(5), 325; https://doi.org/10.3390/cimb47050325
Submission received: 15 March 2025 / Revised: 23 April 2025 / Accepted: 30 April 2025 / Published: 1 May 2025
(This article belongs to the Special Issue Tumor Microenvironment: Crosstalk Between Epigenetics, Metabolism and Immunity)
Browse Figures
Versions Notes

Abstract

:
Cancer-associated sarcopenia is closely linked to the prognosis of cancer patients, making its management a critical aspect of cancer treatment. Branched-chain amino acids (BCAAs) are known to promote skeletal muscle growth in healthy individuals; however, their efficacy in cancer patients remains controversial. In this study, we investigated the effects of BCAAs on cancer-associated sarcopenia to identify the underlying mechanisms that may suppress their effectiveness. In both a mouse cachexia model and an in vitro cachexia model, BCAAs did not significantly reduce oxidative stress, improve oxidative phosphorylation, suppress cytokine production, or enhance muscle mass and maturation, as observed in non-cancer-bearing models. Furthermore, treatment with 5-fluorouracil exacerbated sarcopenia in the mouse cachexia model, independent of tumor weight reduction, and this deterioration was not ameliorated by a BCAA-supplemented diet. The ineffectiveness of BCAAs was attributed to impaired BCAA catabolism, characterized by the decreased expression of branched-chain α-ketoacid dehydrogenase (BCKD) and increased levels of its inactive phosphorylated form, which were driven by elevated expression of BCKD kinase. These metabolic alterations were induced by high-mobility group box-1 (HMGB1). Notably, caprylic acid reversed these impairments in BCAA metabolism, thereby restoring BCAA efficacy. Our findings suggest that enhancing BCAA metabolism may improve their therapeutic potential in the treatment of cancer-associated sarcopenia.

1. Introduction

Sarcopenia is a progressive muscle disease characterized by muscle failure resulting from cumulative deleterious changes over a lifetime [1]. Cachexia is a condition associated with diseases such as cancer, organ failure, and infections, and is characterized by generalized wasting, including, but not limited to, muscle loss, which is termed sarcopenia [2]. Cancer cachexia affects approximately 80% of patients with advanced cancer and 40% of patients across all cancer stages [3,4,5], with elderly cancer patients being particularly vulnerable [6]. Cancer cachexia is a complex metabolic syndrome involving multiple factors, among which skeletal muscle atrophy is a key pathological feature [7,8,9]. Moreover, chemotherapy and certain targeted therapies have been recognized as contributing factors to sarcopenia, leading to reduced physical function and a diminished quality of life [10]. Notably, in cancer patients, the skeletal muscle mass is closely linked to treatment tolerance [11] and is strongly correlated with the overall survival [12].
Key factors implicated in cancer-associated sarcopenia include cancer-related inflammatory cytokines [13,14], increased oxidative stress [15], enhanced catabolism [16], and anorexia [11]. Studies utilizing a mouse cachexia model have demonstrated that elevated oxidative stress and impaired mitochondrial energy metabolism play crucial roles in the progression of cachexia [17]. Additionally, high-mobility group box-1 (HMGB1), an inflammatory cytokine, has been implicated in promoting oxidative stress, inflammatory responses, autophagy, and skeletal muscle aging [13,14,17].
Amino acids play a crucial role in various nutritional interventions aimed at counteracting cancer-related sarcopenia [18]. In response to the increased oxidative stress associated with cancer, the combined use of the antioxidant amino acids cystine and theanine has been shown to effectively reduce sarcopenia [19]. Conversely, branched-chain amino acids (BCAAs), particularly leucine (Leu), are metabolically activated by peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), enhancing energy metabolism and stimulating the mechanistic target of rapamycin complex 1 (mTORC1) to promote protein synthesis [20]. Among the BCAAs, Leu plays a particularly significant role, as its blood concentration is directly related to muscle protein synthesis [21]. In addition to its role in muscle maintenance, the BCAA levels are also linked to appetite regulation. A reduction in BCAA levels is associated with increased serotonin synthesis, which can lead to anorexia [22]. Thus, BCAA supplementation has been shown to improve appetite, making it beneficial for aging-related sarcopenia and overall health maintenance [23,24].
Given its strong anti-anorectic and anti-cachectic effects, BCAA is also considered a promising intervention for cancer-associated sarcopenia [25]. However, despite the growing interest in the role of amino acids in skeletal muscle preservation, the specific mechanisms and clinical effectiveness of BCAA in cancer cachexia remain insufficiently explored. In this study, we aim to investigate the effects of BCAA on cancer-related sarcopenia using a mouse model of cancer cachexia and an in vitro cachexia model that we have previously developed [26,27].

2. Materials and Methods

2.1. Cell Culture

CT26 murine colon carcinoma cells were generously provided by Professor I.J. Fidler (MD Anderson Cancer Center, Houston, TX, USA). C2C12 myoblasts derived from mouse skeletal muscle were obtained from Dainihon Pharmacy Co. (Tokyo, Japan). Both cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA). C2C12 cells were treated with BCAAs (Leu, Ile, and Val, 200 μM each, Wako), HMGB1 (40 μg/mL, BioLegend Inc., San Diego, CA, USA) or caprylic acid (C8) (50 μg/mL, Wako) [28] for 48 h.

2.2. In Vitro Cachexia Model

To model cancer cachexia in vitro [26], the culture medium was supplemented with 20% (v/v) ascitic fluid collected from BALB/c mice previously inoculated with CT26 cells. For the control condition, 20% (v/v) CT26 culture supernatant was added to the medium. A comparison of the compositional differences among standard DMEM, ascites-supplemented medium, and culture supernatant-supplemented medium is provided in Table 1. C2C12 cells were treated with ascites-supplemented medium or culture supernatant-supplemented medium for 48 h.

2.3. Animals

Five-week-old male BALB/c mice were acquired from SLC Japan (Shizuoka, Japan). Mice were housed in a pathogen-free environment with a 12 h light/dark cycle at 22 °C and controlled humidity. All animal procedures adhered to the institutional guidelines approved by the Animal Ethics Committee of Nara Medical University (Approval No. 12777, 20 April 2020) and were consistent with the Japanese Ministry of Health, Labor and Welfare regulations. Mice were allowed to acclimate for one week prior to experimentation.
The cachexia model was established via intraperitoneal injection of CT26 cells, as previously described [27]. Each experimental group contained five mice. For chemotherapy treatment, 5-fluorouracil (5FU; Wako) was administered subcutaneously at a dose of 30 mg/kg once weekly. The quadriceps femoris muscle (QFM) was isolated post-euthanasia. Tumor burden was evaluated by gross dissection of peritoneal tumor masses from the abdominal wall, mesentery, diaphragm, and intestines.

2.4. Dietary Interventions

Mice were fed either a control diet (CE-2; CLEA Japan, Tokyo, Japan), a branched-chain amino acid (BCAA)-supplemented diet, or a diet enriched with both BCAAs and 2% (w/w) C8 (Wako). Diet formulations are detailed in Table 2. Food and caloric intake per mouse were calculated from the cumulative daily intake of each group (n = 5).

2.5. Protein Extraction

Proteins were extracted from C2C12 cells and mouse QFM as previously reported [28]. Whole-cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer containing 0.1% SDS (Thermo Fisher Scientific, Tokyo, Japan). Total protein concentrations were measured using the Rapid Protein Assay Kit (Wako).

2.6. Western Blotting

Equal amounts of protein were resolved on 10% SDS-PAGE gels and transferred onto nitrocellulose membranes. Membranes were incubated with specific primary antibodies (Table 3), followed by HRP-conjugated secondary antibodies (P0217; Dako, Glostrup, Denmark). Protein bands were visualized using the Fusion Solo imaging system (M&S Instruments, Osaka, Japan).

2.7. Enzyme-Linked Immunosorbent Assay (ELISA) and Fluorometric Analysis

The levels of MYL1, HMGB1, TNF-α, GSH/GSSG, 4-hydroxynonenal (4HNE), BCAAs, and acetyl-CoA were quantified using commercial ELISA kits according to the manufacturers’ protocols (Table 3), using whole-cell lysates.

2.8. Mitochondrial Stress Test (Seahorse Assay)

Mitochondrial and glycolytic functions were assessed using the Seahorse XFe24 Extracellular Flux Analyzer (Agilent Technologies, Chicopee, MA, USA), as described previously [26]. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in C2C12 cells (1 × 104 cells/well) using the Seahorse XF24 FluxPak (SeahorseBioscience, North Billerica, MA, USA).

2.9. Glycolytic Stress Test

Glycolytic activity was analyzed using a modified glycolytic stress test with the Seahorse XFe24 platform. Prior to measurement, C2C12 cells were cultured in 6-well plates with either ascitic fluid or CT26-conditioned medium. For the assay, cells were seeded at 1 × 104 cells/well in XF Base Medium supplemented with 200 mM L-glutamine and 5 mM HEPES. Sensor cartridges were hydrated in XF Calibrant 24 h before use. The following compounds were sequentially injected: glucose (10 mM), oligomycin (1 µM), rotenone and antimycin A (1 µM each), and 2-deoxyglucose (50 mM). The combined rotenone/antimycin injection enabled evaluation of mitochondrial contributions to ECAR through glycolytic intermediates entering the TCA cycle.

2.10. Reverse Transcription–Polymerase Chain Reaction (RT-PCR)

Total RNA (0.5 µg) from cultured cells was isolated using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA). RT-PCR was performed using primer pairs listed in Table 3 (synthesized by Sigma Genosys, St. Louis, MO, USA) to evaluate gene expression. PCR products were resolved on 2% agarose gels and visualized by ethidium bromide staining. ACTB mRNA served as an internal reference.

2.11. Statistical Analysis

Statistical analyses were conducted using one-way ANOVA with Bonferroni’s post hoc correction in GraphPad InStat software (v3.1; GraphPad Software Inc., La Jolla, CA, USA). Results are presented as mean ± SD from at least three independent experiments. A p-value < 0.05 was considered statistically significant. Bonferroni-adjusted significance thresholds were calculated based on the number of comparisons performed, but results were reported using the conventional p < 0.05 notation when significance was achieved.

3. Results

3.1. Effect of BCAAs on Cancer Sarcopenia

To investigate the effects of BCAAs on cancer-associated cachexia, we first examined its impact using a cachexia model, as BCAAs are known to promote muscle growth in healthy individuals. The mouse cachexia model was established by intraperitoneal inoculation of syngeneic BALB/c mice with CT26 murine colon cancer cells [27]. The control group (Cont) consisted of non-tumor-inoculated mice fed a standard diet (CD), while the tumor-inoculated group was divided into two subgroups: one receiving the CD diet and the other receiving a BCAA-supplemented diet (Figure 1A). No significant differences were observed among the groups in terms of food intake, body weight changes, or tumor weight (Figure 1B–D).
The weight of the quadriceps femoris muscle (QCM) decreased by 48% in the BCAA group compared to the Cont group, with no significant difference observed between the CD and BCAA groups (Figure 2A). Additionally, the sodium dodecyl sulfate-soluble myosin light chain-1 (SDS-MYL1) content, a marker of muscle maturity, was significantly reduced in both the CD and BCAA groups (6 pg/g and 9 pg/g, respectively) compared to the Cont group (56 pg/g) (Figure 2B). Oxidative stress, indicated by elevated levels of 4-hydroxynonenal (4HNE), was significantly increased, while the glutathione/glutathione disulfide (GSH/GSSG) ratio was markedly reduced in both the CD and BCAA groups compared to in the Cont group (Figure 2C,D). Furthermore, the intramuscular concentrations of TNF-α and HMGB1, which are associated with cachexia [13], were significantly elevated in both the CD and BCAA groups compared to in the Cont group, with no significant differences between the CD and BCAA groups (Figure 2E). These findings indicate that BCAA supplementation alone did not mitigate muscle loss or inflammatory responses in the cachexia model.

3.2. Effects of BCAAs on Cancer-Related Impairment of Energy Metabolism

Next, we investigated the effects of BCAAs on mitochondrial energy metabolism using an in vitro cachexia model [26], in which C2C12 mouse myoblasts were treated with ascites fluid derived from the aforementioned cachexia model (Figure 3). The ascites treatment significantly reduced the basal respiration, maximal respiration, ATP production, and spare respiratory capacity to approximately half the levels observed in the non-ascites control (Cont) group (Figure 3A–F). In the Asc + BCAA treatment group, the basal and maximal respiration recovered to levels comparable to the control. However, ATP production remained lower than that observed with the ascites treatment alone, likely due to an increase in proton leakage (Figure 3E). Additionally, an extracellular acidification rate (ECAR) analysis was performed to evaluate glycolysis and lactate fermentation (Figure 3G,H). The ascites treatment led to a decrease in the ECAR, which was subsequently improved by the BCAA treatment. These results suggest that while BCAA supplementation enhances mitochondrial respiration, its effects on ATP production remain uncertain due to the increased proton leakage.

3.3. BCAA Metabolism in the Cachexia Models

Given the previously reported metabolic impairments of BCAAs in diabetes mellitus and cancer [29,30], we examined BCAA metabolism in the in vitro cachexia model (Figure 4). Specifically, we analyzed alterations in the branched-chain α-ketoacid dehydrogenase (BCKD) complex, which is involved in BCAA catabolism, and its regulatory enzyme, branched-chain α-ketoacid dehydrogenase kinase (BDK) (Figure 4A). The ascites treatment led to a decrease in the BCKD protein levels, an increase in phosphorylated (inactive) BCKD, and the upregulation of BDK expression. The BCAA treatment did not restore these alterations. Moreover, the intramuscular BCAA levels were significantly elevated following the ascites treatment and were further increased in the Asc + BCAA treatment group (Figure 4B). In contrast, the intramuscular acetyl AcCoA levels were reduced following the ascites treatment, and this reduction was exacerbated by the combined Asc + BCAA treatment (Figure 4C). These findings suggest that impaired BCAA metabolism in cancer cachexia leads to its accumulation and limits its protective effects on skeletal muscle.
To further explore the underlying mechanisms, we examined the role of inflammatory cytokines in inhibiting BCAA utilization. The treatment of the C2C12 myoblasts with HMGB1 (40 μg/mL) led to the downregulation of PGC1α and BCKD gene expression, while BDK was upregulated (Figure 4D). HMGB1 also induced BCAA retention within the C2C12 cells (Figure 4E) while significantly reducing the AcCoA levels (Figure 4F). These findings indicate that HMGB1 suppresses BCAA metabolism by inhibiting BCKD activity.
Next, we investigated whether inhibiting BDK could restore BCAA metabolism. C8, a known BDK inhibitor [31], was used as a treatment. The co-treatment of the C2C12 cells with HMGB1 (40 μg/mL) and C8 (50 μg/mL) reversed HMGB1-induced BCAA retention (Figure 4G) and restored the AcCoA levels (Figure 4H). These results suggest that targeting BDK with C8 may enhance BCAA metabolism and improve muscle preservation in cancer cachexia.

3.4. Effects of C8 on HMGB1-Induced Skeletal Muscle Impairment

To further evaluate the effects of C8 on skeletal muscle function, we cultured C2C12 myoblasts in normal medium and examined the impact of BCAAs on energy metabolism (Figure 5A–F). The HMGB1 treatment suppressed basal respiration and ATP production, but co-treatment with C8 restored these functions to levels exceeding those of the control group (Figure 5B–D). Maximum respiration, which was enhanced by BCAAs alone but suppressed by HMGB1, was also restored by C8 (Figure 5C). Proton leakage, which was reduced in the BCAA + HMGB1 group, returned to control levels following the C8 treatment (Figure 5E). Additionally, the C8 treatment restored the SDS-MYL1 levels and reduced oxidative stress (4HNE levels) in the HMGB1-treated cells (Figure 5G,H). These findings suggest that C8 alleviates HMGB1-induced impairments in skeletal muscle metabolism and function, thereby enhancing the muscle-protective effects of BCAAs in cancer cachexia.

3.5. Effect of BCAAs When Combined with 5FU Treatment in a Mouse Cachexia Model

Finally, we investigated the impact of chemotherapy on sarcopenia and the potential protective effects of BCAA supplementation in this context (Figure 6). 5FU (30 mg/kg/week) was administered to mice with cachexia receiving a BCAA-supplemented diet. No significant differences were observed in body weight among the five experimental groups (Figure 6B). However, the tumor weight was reduced by 55% in the BCAA + 5FU group compared to that in the tumor-alone group (Figure 6C). The quadriceps femoris muscle weight and SDS-MYL1 levels were not rescued by BCAA supplementation alone and were further reduced by 5FU. However, the addition of C8 effectively restored muscle maturity and reduced oxidative stress (Figure 6E,F). These findings suggest that while BCAAs alone do not protect against chemotherapy-induced sarcopenia, their combination with C8 enhances muscle preservation.

4. Discussion

In this study, we examined the effects of BCAAs on cancer-associated sarcopenia and found that BCAAs did not exert the expected protective effects on muscle that are typically observed in healthy individuals due to the impairment of BCAA metabolism via BCKD inactivation. An inflammatory cytokine, HMGB1, inactivated BCKD, which was restored by C8 treatment.
BCAAs are widely recognized as effective supplements for enhancing muscle mass and function, particularly when combined with exercise [32,33,34]. Among BCAAs, Leu has garnered particular attention for its ability to stimulate acute anabolic responses [35]. Additionally, low BCAA concentrations in individuals with sarcopenia suggest a potential therapeutic role for BCAA supplementation in muscle preservation [36]. Furthermore, BCAAs have been shown to upregulate gene expression related to mitochondrial biogenesis and function in skeletal muscle affected by cancer sarcopenia [37]. However, the effects of BCAA supplementation in conditions such as sepsis, cancer, diabetes, and obesity remain uncertain, necessitating further investigation [38].
This study demonstrated that impaired BCAA utilization in cancer patients compromises the muscle-protective effects of BCAAs. Elevated blood BCAA levels have been observed in cancer patients, suggesting a disruption in BCAA metabolism [39]. Although the exact mechanisms remain unclear, several factors have been implicated. Thyroid hormone, which is elevated during starvation, has been shown to promote the expression of BDK, leading to impaired BCAA utilization [40]. Notably, increased blood thyroid hormone levels have been reported in cancer patients [41,42]. Moreover, BDK has been identified as a key regulator of metabolic reprogramming in cancer cachexia [30]. The suppression of BCKD activity may contribute to the observed impairment in BCAA utilization in cancer patients.
HMGB1 functions as an autocrine/paracrine growth factor in various cancers, promoting malignant phenotypes and disease recurrence [43]. Additionally, HMGB1 has been shown to exacerbate cancer-associated sarcopenia [13,14,17]. In this study, BCAA supplementation did not suppress the expression of either TNFα or HMGB1. Notably, BCAAs have been reported to promote cytokine production when accumulated in excess [29], which is consistent with our findings. Furthermore, we demonstrated that HMGB1 promotes the expression of BDK by downregulating PGC1α, thereby inhibiting BCKD and reducing BCAA metabolism.
BCAA metabolism consists of two key processes: the conversion of BCAAs to branched-chain α-keto acids (BCKAs) via cytoplasmic or mitochondrial branched-chain aminotransferase (BCAT), followed by BCKA degradation in mitochondria by BCKD. This degradation produces acetyl-CoA, propionyl-CoA, and 2-methylbutyryl-CoA, which are subsequently utilized for ATP generation [44]. In this study, treatment with cancer ascites led to decreased BCKD expression, increased BDK expression, and enhanced phosphorylation of BCKD, resulting in impaired BCAA metabolism. A similar inactivation of the BCKD complex has been observed in multiple organs (liver, muscle, and kidneys) in diabetes, leading to organ damage [29]. Dysfunctional BCKD activity has also been linked to cardiac dysfunction, systolic ventricular dilation, and abnormal gene expression in the myocardium [45]. Impaired BCAA catabolism, characterized by BCAA and BCKA retention due to decreased BCKD function, results in mitochondrial oxidative stress, redox imbalance, inflammation, tissue fibrosis, and increased cytokine production via macrophage hyperactivation [29]. Our findings indicate that such BCAA catabolic impairment hinders the beneficial effects of BCAA supplementation in ameliorating cancer sarcopenia.
BCKD dysfunction can arise not only from genetic disorders such as maple syrup urine disease but also from factors including fatty acids, inflammatory cytokines, oxidative stress, and elevated insulin levels [44,46]. Our data suggest that HMGB1 in cancer ascites suppresses PGC1α expression while activating BDK, thereby impairing BCAA utilization in C2C12 cells. Extracellular HMGB1 has previously been reported to downregulate PGC1α expression and inhibit mitochondrial biogenesis [47,48]. In contrast, cytoplasmic HMGB1 has been shown to bind to cytoplasmic toll-like receptor-9 (TLR9) to promote PGC1α expression and mitochondrial biogenesis [49]. As an inflammatory cytokine, HMGB1 is believed to primarily exert the former effect.
Although the relationship between inflammatory cytokines and impaired BCAA metabolism has not been fully elucidated, our findings suggest that this mechanism may contribute to the pathogenesis of cancer sarcopenia. HMGB1 has been implicated in cancer-associated sarcopenia [13,27,50,51,52,53], cancer-related cardiac dysfunction [26,52], and skeletal muscle aging [17]. The induction of BCAA metabolic impairment by HMGB1 may be a contributing factor to these disorders. HMGB1 has a mutual induction relationship with inflammatory cytokines such as TNFα, forming a vicious cycle. Future investigations into whether cytokines other than HMGB1 are involved in BCAA metabolic disorders will be useful in elucidating the mechanism of cancer sarcopenia.
To maximize the therapeutic effects of BCAAs in cancer-associated sarcopenia, it is essential to address the underlying impairment in BCAA catabolism. The inhibition of BDK, the enzyme responsible for phosphorylating and inactivating BCKD, or the overexpression of protein phosphatase-1K (PPM1K), which dephosphorylates and activates BCKD, has been reported to reduce circulating BCAA levels, alleviate hepatic steatosis, and improve glucose tolerance [53]. To find food components that restore BCKD activity, we investigated the effects of food ingredients that we have previously investigated (lauric acid, capric acid, caprylic acid, berberine, and pterostilbene) and found that C8 restored BCKD activity. We also found that C8 has been reported to possess BDK inhibitory activity [31]. Our previous studies have demonstrated that C8 exerts a strong protective effect on skeletal muscle [28]. Additionally, C8 enhances mitochondrial turnover and improves mitochondrial quality control. The findings of this study suggest that C8 restores BCKD activity by inhibiting BDK, thereby ameliorating impaired BCAA utilization. These results indicate that the muscle-protective effects of BCAAs in cancer patients may be enhanced by molecularly targeting BDK.
Previous studies have reported that glucocorticoids and PPARα ligands suppress BDK expression [40,54]. Investigating their effects on cancer sarcopenia, as well as developing more potent BDK inhibitors, could provide more effective therapeutic strategies for managing cancer sarcopenia. Although targeting different molecules, the inhibition of mitochondrial pyruvate carrier has been shown to improve BCAA metabolism in diabetic patients [55].
Given the importance of BDK inhibition in restoring BCAA metabolism, we explored additional mechanisms that may further optimize BCAA utilization. Notably, BCKD activity is suppressed by reactive nitrogen species produced by cytokines [56]. While cystine and theanine have been reported to independently mitigate sarcopenia by reducing oxidative stress [19], they may also attenuate BCKD inhibition, thereby improving BCAA utilization. Unlike C8, cystine and theanine likely enhance BCAA metabolism through distinct mechanisms, potentially amplifying their therapeutic effects against sarcopenia.
In the mouse cachexia model, treatment with 5FU reduced the tumor weight but simultaneously increased oxidative stress in skeletal muscle, leading to suppressed QCM weight and reduced muscle maturity. These findings suggest that anticancer drug treatment exacerbates sarcopenia through oxidative stress induction. However, in C2C12 myoblasts treated with cancer ascites, BCAA supplementation promoted oxidative phosphorylation and glycolysis but failed to increase ATP production due to excessive proton leakage, ultimately resulting in an insufficient protective effect on muscle weight and maturity. In contrast, C8 supplementation effectively ameliorated 5FU-induced sarcopenia when combined with BCAAs. These results suggest that BCAA supplementation, when coupled with metabolic enhancement, may also be beneficial in mitigating chemotherapy-induced sarcopenia.
However, chemotherapy-induced sarcopenia remains an underexplored area, and this study only examined the effects of 5FU. Future investigations should assess whether other chemotherapeutic agents exert similar effects and whether metabolic enhancement strategies remain effective across a broader range of anticancer treatments. Additionally, given that this study was conducted using a murine model, further research is needed to confirm whether similar metabolic alterations occur in human cancer patients.
We used an in vitro cachexia model to investigate impaired BCAA utilization. Many studies have reported that humoral factors such as inflammatory cytokines play an important role in the development of cachexia [7,8,9]. We have obtained similar results [13,14]. Meanwhile, the cancer ascites generated in our mouse cachexia model contains various inflammatory cytokines, which correlate with the development of cachexia [26,27]. To establish an in vitro cachexia model, we devised a method to treat C2C12 cells with cachexia-related humoral factors in ascites by mixing the cancer ascites with the culture medium [26]. This system has, so far, produced results that correlate well with the mouse model, and is considered to be useful as an in vitro model of sarcopenia due to cachexia [19,26,52]. One problem is that it is not yet fully clear what factors are contained in the ascites other than the inflammatory cytokines already detected. It has also not been determined to what extent the components in the blood of tumor-bearing bodies and the components in the cancer ascites are the same. This should be elucidated in the future using metabolomics or proteomics.
At the systemic level, hepatocytes play a crucial role in BCAA metabolism. In this study, we did not examine BDK expression changes in hepatocytes, highlighting an area for further investigation. Additionally, we did not monitor alterations in BCKA concentrations. Since excessive BCKA accumulation has been associated with potential toxicity and organ damage [57], future studies should incorporate high-performance liquid chromatography (HPLC) analysis to assess the BCKA levels more precisely. Furthermore, early rodent studies suggested strong muscle-protective effects of BCAAs; however, recent detailed investigations have yielded conflicting results [30]. Considering this discrepancy, the findings of our study, which are based on a murine model, require further validation in human subjects.

5. Conclusions

Our findings suggest that the therapeutic effects of BCAAs in cancer-associated sarcopenia could be enhanced to levels comparable to those observed in healthy individuals by normalizing BCAA metabolism. Addressing BCAA metabolic impairments may expand dietary intervention options for cancer sarcopenia, offering a novel strategy for improving patient outcomes.

Author Contributions

Study concept and design: R.F.-T. and H.K. Data investigation: I.K., T.M., S.N., R.N., Y.M., K.G., and R.O. Data analysis: I.K., H.O., K.F., Y.L., T.S., and C.N. Drafting the manuscript: I.K. Editing the manuscript: R.F.-T. and H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by MEXT KAKENHI Grant Numbers 22K11423 (I.K.), 19K16564 (R.F.-T.), 23K10481 (H.O.), 21K11223 (K.F.), 22K17655 (K.G.), and 20K21659 (H.K.).

Institutional Review Board Statement

Animal experiments were performed in accordance with the institutional guidelines approved by the Committee for Animal Experimentation of Nara Medical University, Kashihara, Japan, following current regulations and standards of the Japanese Ministry of Health, Labor and Welfare (approval no. 12777, 20 April 2020).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are contained within the article.

Acknowledgments

The authors thank Tomomi Nitta for her expert assistance with the preparation of this manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

BCAAbranched-chain amino acid
BCKDbranched-chain α-ketoacid dehydrogenase
HMGB1high-mobility group box-1
QCMquadriceps femoris muscle
SDS-MYL1sodium dodecyl sulfate-soluble myosin light chain-1
4HNE4-hydroxynonenal
TNFtumor necrosis factor
BDKBCKD kinase
AcCoAacetyl coenzyme A
PGC1αperoxisome proliferator-activated receptor-γ coactivator-1α
C8caprylic acid

References

  1. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef] [PubMed]
  2. Ferrer, M.; Anthony, T.G.; Ayres, J.S.; Biffi, G.; Brown, J.C.; Caan, B.J.; Cespedes Feliciano, E.M.; Coll, A.P.; Dunne, R.F.; Goncalves, M.D.; et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell 2023, 186, 1824–1845. [Google Scholar] [CrossRef] [PubMed]
  3. Bozzetti, F. Screening the nutritional status in oncology: A preliminary report on 1000 outpatients. Support. Care Cancer 2009, 17, 279–284. [Google Scholar] [CrossRef] [PubMed]
  4. Morena da Silva, F.; Lim, S.; Cabrera, A.R.; Schrems, E.R.; Jones, R.G.; Rosa-Caldwell, M.E.; Washington, T.A.; Murach, K.A.; Greene, N.P. The time-course of cancer cachexia onset reveals biphasic transcriptional disruptions in female skeletal muscle distinct from males. BMC Genom. 2023, 24, 374. [Google Scholar] [CrossRef]
  5. Blum, D.; Stene, G.B.; Solheim, T.S.; Fayers, P.; Hjermstad, M.J.; Baracos, V.E.; Fearon, K.; Strasser, F.; Kaasa, S. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—A study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 2014, 25, 1635–1642. [Google Scholar] [CrossRef]
  6. Paillaud, E.; Caillet, P.; Campillo, B.; Bories, P.N. Increased risk of alteration of nutritional status in hospitalized elderly patients with advanced cancer. J. Nutr. Health Aging 2006, 10, 91–95. [Google Scholar]
  7. Evans, W.J.; Morley, J.E.; Argiles, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; et al. Cachexia: A new definition. Clin. Nutr. 2008, 27, 793–799. [Google Scholar] [CrossRef]
  8. Fearon, K.C.; Voss, A.C.; Hustead, D.S. Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 2006, 83, 1345–1350. [Google Scholar] [CrossRef]
  9. Fearon, K.C. Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur. J. Cancer 2008, 44, 1124–1132. [Google Scholar] [CrossRef]
  10. Davis, M.P.; Panikkar, R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann. Palliat. Med. 2019, 8, 86–101. [Google Scholar] [CrossRef]
  11. Fearon, K.; Arends, J.; Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 2013, 10, 90–99. [Google Scholar] [CrossRef] [PubMed]
  12. Shachar, S.S.; Williams, G.R.; Muss, H.B.; Nishijima, T.F. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur. J. Cancer 2016, 57, 58–67. [Google Scholar] [CrossRef] [PubMed]
  13. Ohmori, H.; Kawahara, I.; Mori, T.; Nukaga, S.; Luo, Y.; Kishi, S.; Fujiwara-Tani, R.; Mori, S.; Goto, K.; Sasaki, T.; et al. Evaluation of Parameters for Cancer-Induced Sarcopenia in Patients Autopsied after Death from Colorectal Cancer. Pathobiology 2019, 86, 306–314. [Google Scholar] [CrossRef] [PubMed]
  14. Luo, Y.; Yoneda, J.; Ohmori, H.; Sasaki, T.; Shimbo, K.; Eto, S.; Kato, Y.; Miyano, H.; Kobayashi, T.; Sasahira, T.; et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res. 2014, 74, 330–340. [Google Scholar] [CrossRef]
  15. Martin, A.; Gallot, Y.S.; Freyssenet, D. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: Data analysis from preclinical and clinical studies. J. Cachexia Sarcopenia Muscle 2023, 14, 1150–1167. [Google Scholar] [CrossRef]
  16. Shyh-Chang, N. Metabolic Changes During Cancer Cachexia Pathogenesis. Adv. Exp. Med. Biol. 2017, 1026, 233–249. [Google Scholar]
  17. Luo, Y.; Fujiwara-Tani, R.; Kawahara, I.; Goto, K.; Nukaga, S.; Nishida, R.; Nakashima, C.; Sasaki, T.; Miyagawa, Y.; Ogata, R.; et al. Cancerous Conditions Accelerate the Aging of Skeletal Muscle via Mitochondrial DNA Damage. Int. J. Mol. Sci. 2024, 25, 7060. [Google Scholar] [CrossRef]
  18. Prado, C.M.; Purcell, S.A.; Laviano, A. Nutrition interventions to treat low muscle mass in cancer. J. Cachexia Sarcopenia Muscle 2020, 11, 366–380. [Google Scholar] [CrossRef]
  19. Nukaga, S.; Fujiwara-Tani, R.; Mori, T.; Kawahara, I.; Nishida, R.; Miyagawa, Y.; Goto, K.; Ohmori, H.; Fujii, K.; Sasaki, T.; et al. Effects of Antioxidant Amino Acids on Cancer Sarcopenia. Int. J. Mol. Sci. 2024, 26, 272. [Google Scholar] [CrossRef]
  20. Kamei, Y.; Hatazawa, Y.; Uchitomi, R.; Yoshimura, R.; Miura, S. Regulation of Skeletal Muscle Function by Amino Acids. Nutrients 2020, 12, 261. [Google Scholar] [CrossRef]
  21. Zaromskyte, G.; Prokopidis, K.; Ioannidis, T.; Tipton, K.D.; Witard, O.C. Evaluating the Leucine Trigger Hypothesis to Explain the Post-prandial Regulation of Muscle Protein Synthesis in Young and Older Adults: A Systematic Review. Front. Nutr. 2021, 8, 685165. [Google Scholar] [CrossRef] [PubMed]
  22. Aguilera, A.; Selgas, R.; Diéz, J.J.; Bajo, M.A.; Codoceo, R.; Alvarez, V. Anorexia in end-stage renal disease: Pathophysiology and treatment. Expert. Opin. Pharmacother. 2001, 2, 1825–1838. [Google Scholar] [PubMed]
  23. Cochet, C.; Belloni, G.; Buondonno, I.; Chiara, F.; D’Amelio, P. The Role of Nutrition in the Treatment of Sarcopenia in Old Patients: From Restoration of Mitochondrial Activity to Improvement of Muscle Performance, a Systematic Review. Nutrients 2023, 15, 3703. [Google Scholar] [CrossRef] [PubMed]
  24. Le Couteur, D.G.; Solon-Biet, S.M.; Cogger, V.C.; Ribeiro, R.; de Cabo, R.; Raubenheimer, D.; Cooney, G.J.; Simpson, S.J. Branched chain amino acids, aging and age-related health. Ageing Res. Rev. 2020, 64, 101198. [Google Scholar] [CrossRef]
  25. Laviano, A.; Muscaritoli, M.; Cascino, A.; Preziosa, I.; Inui, A.; Mantovani, G.; Rossi-Fanelli, F. Branched-chain amino acids: The best compromise to achieve anabolism? Curr. Opin. Clin. Nutr. Metab. Care 2005, 8, 408–414. [Google Scholar] [CrossRef]
  26. Nukaga, S.; Mori, T.; Miyagawa, Y.; Fujiwara-Tani, R.; Sasaki, T.; Fujii, K.; Mori, S.; Goto, K.; Kishi, S.; Nakashima, C.; et al. Combined administration of lauric acid and glucose improved cancer-derived cardiac atrophy in a mouse cachexia model. Cancer Sci. 2020, 111, 4605–4615. [Google Scholar] [CrossRef]
  27. Mori, T.; Ohmori, H.; Luo, Y.; Mori, S.; Miyagawa, Y.; Nukaga, S.; Goto, K.; Fujiwara-Tani, R.; Kishi, S.; Sasaki, T.; et al. Giving combined medium-chain fatty acids and glucose protects against cancer-associated skeletal muscle atrophy. Cancer Sci. 2019, 110, 3391–3399. [Google Scholar] [CrossRef]
  28. Nishida, R.; Nukaga, S.; Kawahara, I.; Miyagawa, Y.; Goto, K.; Nakashima, C.; Luo, Y.; Sasaki, T.; Fujii, K.; Ohmori, H.; et al. Differential Effects of Three Medium-Chain Fatty Acids on Mitochondrial Quality Control and Skeletal Muscle Maturation. Antioxidants 2024, 13, 821. [Google Scholar] [CrossRef]
  29. Liu, S.; Li, L.; Lou, P.; Zhao, M.; Wang, Y.; Tang, M.; Gong, M.; Liao, G.; Yuan, Y.; Li, L.; et al. Elevated branched-chain α-keto acids exacerbate macrophage oxidative stress and chronic inflammatory damage in type 2 diabetes mellitus. Free Radic. Biol. Med. 2021, 175, 141–154. [Google Scholar] [CrossRef]
  30. Chen, L.; Zhang, H.; Chi, M.; Wang, Y.; Zhu, X.; Han, L.; Xin, B.; Gan, R.; Tu, Y.; Sun, X.; et al. Bckdk-Mediated Branch Chain Amino Acid Metabolism Reprogramming Contributes to Muscle Atrophy during Cancer Cachexia. Mol. Nutr. Food Res. 2024, 68, e2300577. [Google Scholar] [CrossRef]
  31. Paxton, R.; Harris, R.A. Regulation of branched-chain α-ketoacid dehydrogenase kinase. Arch. Biochem. Biophys. 1984, 231, 48–57. [Google Scholar] [CrossRef] [PubMed]
  32. Shimomura, Y.; Murakami, T.; Nakai, N.; Nagasaki, M.; Harris, R.A. Exercise promotes BCAA catabolism: Effects of BCAA supplementation on skeletal muscle during exercise. J. Nutr. 2004, 134 (Suppl. 6), 1583S–1587S. [Google Scholar] [CrossRef] [PubMed]
  33. Aoyama, S.; Kim, H.K.; Hirooka, R.; Tanaka, M.; Shimoda, T.; Chijiki, H.; Kojima, S.; Sasaki, K.; Takahashi, K.; Makino, S.; et al. Distribution of dietary protein intake in daily meals influences skeletal muscle hypertrophy via the muscle clock. Cell Rep. 2021, 36, 109336. [Google Scholar] [CrossRef] [PubMed]
  34. Plotkin, D.L.; Delcastillo, K.; Van Every, D.W.; Tipton, K.D.; Aragon, A.A.; Schoenfeld, B.J. Isolated Leucine and Branched-Chain Amino Acid Supplementation for Enhancing Muscular Strength and Hypertrophy: A Narrative Review. Int. J. Sport. Nutr. Exerc. Metab. 2021, 31, 292–301. [Google Scholar] [CrossRef]
  35. Rieu, I.; Balage, M.; Sornet, C.; Giraudet, C.; Pujos, E.; Grizard, J.; Mosoni, L.; Dardevet, D. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia. J. Physiol. 2006, 575 Pt 1, 305–315. [Google Scholar] [CrossRef]
  36. Liu, X.; Wu, J.; Tang, J.; Xu, Z.; Zhou, B.; Liu, Y.; Hu, F.; Zhang, G.; Cheng, R.; Xia, X.; et al. Prevotella copri alleviates sarcopenia via attenuating muscle mass loss and function decline. J. Cachexia Sarcopenia Muscle 2023, 14, 2275–2288. [Google Scholar] [CrossRef]
  37. Tanada, Y.; Shioi, T.; Kato, T.; Kawamoto, A.; Okuda, J.; Kimura, T. Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci. 2015, 137, 20–27. [Google Scholar] [CrossRef]
  38. Holeček, M. Branched-chain amino acids in health and disease: Metabolism, alterations in blood plasma, and as supplements. Nutr. Metab. 2018, 15, 33. [Google Scholar] [CrossRef]
  39. Argiles, J.; Costelli, P.; Carbo, N.; Lopezsoriano, F. Branched-chain amino acid catabolism and cancer cachexia (review). Oncol. Rep. 1996, 3, 687–690. [Google Scholar] [CrossRef]
  40. Harris, R.A.; Kobayashi, R.; Murakami, T.; Shimomura, Y. Regulation of branched-chain α-keto acid dehydrogenase kinase expression in rat liver. J. Nutr. 2001, 131, 841S–845S. [Google Scholar] [CrossRef]
  41. Shimi, G.; Zand, H.; Pourvali, K.; Ghorbani, A. Colorectal cancer causes alteration of thyroid hormone profile in newly diagnosed patients. Expert. Rev. Endocrinol. Metab. 2021, 16, 259–262. [Google Scholar] [CrossRef] [PubMed]
  42. Petranović Ovčariček, P.; Deandreis, D.; Giovanella, L. Thyroid dysfunctions induced by molecular cancer therapies: A synopsis for nuclear medicine thyroidologists. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3355–3360. [Google Scholar] [CrossRef] [PubMed]
  43. Ohmori, H.; Luo, Y.; Kuniyasu, H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert. Opin. Ther. Targets 2011, 15, 183–193. [Google Scholar] [CrossRef] [PubMed]
  44. Bloomgarden, Z. Diabetes and branched-chain amino acids: What is the link? J. Diabetes 2018, 10, 350–352. [Google Scholar] [CrossRef]
  45. Yu, J.Y.; Cao, N.; Rau, C.D.; Lee, R.P.; Yang, J.; Flach, R.J.R.; Petersen, L.; Zhu, C.; Pak, Y.L.; Miller, R.A.; et al. Cell-autonomous effect of cardiomyocyte branched-chain amino acid catabolism in heart failure in mice. Acta Pharmacol. Sin. 2023, 44, 1380–1390. [Google Scholar] [CrossRef]
  46. Blackburn, P.R.; Gass, J.M.; Vairo, F.P.E.; Farnham, K.M.; Atwal, H.K.; Macklin, S.; Klee, E.W.; Atwal, P.S. Maple syrup urine disease: Mechanisms and management. Appl. Clin. Genet. 2017, 10, 57–66. [Google Scholar] [CrossRef]
  47. Bhat, S.M.; Massey, N.; Shrestha, D.; Karriker, L.A.; Jelesijević, T.; Wang, C.; Charavaryamath, C. Transcriptomic and ultrastructural evidence indicate that anti-HMGB1 antibodies rescue organic dust-induced mitochondrial dysfunction. Cell Tissue Res. 2022, 388, 373–398. [Google Scholar] [CrossRef]
  48. Hasegawa, A.; Iwasaka, H.; Hagiwara, S.; Asai, N.; Nishida, T.; Noguchi, T. Alternate day calorie restriction improves systemic inflammation in a mouse model of sepsis induced by cecal ligation and puncture. J. Surg. Res. 2012, 174, 136–141. [Google Scholar] [CrossRef]
  49. Tohme, S.; Yazdani, H.O.; Liu, Y.; Loughran, P.; van der Windt, D.J.; Huang, H.; Simmons, R.L.; Shiva, S.; Tai, S.; Tsung, A. Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction. Hepatology 2017, 66, 182–197. [Google Scholar] [CrossRef]
  50. Narasimhulu, C.A.; Singla, D.K. BMP-7 Attenuates Sarcopenia and Adverse Muscle Remodeling in Diabetic Mice via Alleviation of Lipids, Inflammation, HMGB1, and Pyroptosis. Antioxidants 2023, 12, 331. [Google Scholar] [CrossRef]
  51. Ho, T.L.; Tang, C.H.; Chang, S.L.; Tsai, C.H.; Chen, H.T.; Su, C.M. HMGB1 Promotes In Vitro and In Vivo Skeletal Muscle Atrophy through an IL-18-Dependent Mechanism. Cells 2022, 11, 3936. [Google Scholar] [CrossRef] [PubMed]
  52. Nukaga, S.; Fujiwara-Tani, R.; Nishida, R.; Miyagawa, Y.; Goto, K.; Kawahara, I.; Nakashima, C.; Fujii, K.; Ogata, R.; Ohmori, H.; et al. Caprylic Acid Inhibits High Mobility Group Box-1-Induced Mitochondrial Damage in Myocardial Tubes. Int. J. Mol. Sci. 2024, 25, 8081. [Google Scholar] [CrossRef] [PubMed]
  53. White, P.J.; McGarrah, R.W.; Grimsrud, P.A.; Tso, S.C.; Yang, W.H.; Haldeman, J.M.; Grenier-Larouche, T.; An, J.; Lapworth, A.L.; Astapova, I.; et al. The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase. Cell Metab. 2018, 27, 1281–1293.e7. [Google Scholar] [CrossRef] [PubMed]
  54. Wang, X.; Price, S.R. Differential regulation of branched-chain α-ketoacid dehydrogenase kinase expression by glucocorticoids and acidification in LLC-PK1-GR101 cells. Am. J. Physiol. Renal Physiol. 2004, 286, F504–F508. [Google Scholar] [CrossRef]
  55. Ferguson, D.; Eichler, S.J.; Yiew, N.K.H.; Colca, J.R.; Cho, K.; Patti, G.J.; Shew, T.M.; Lutkewitte, A.J.; Mukherjee, S.; McCommis, K.S.; et al. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism. Mol. Metab. 2023, 70, 101694. [Google Scholar] [CrossRef]
  56. Arp, N.L.; Seim, G.L.; Votava, J.A.; Josephson, J.; Fan, J. Reactive nitrogen species inhibit branched chain α-ketoacid dehydrogenase complex and impact muscle cell metabolism. J. Biol. Chem. 2023, 299, 105333. [Google Scholar] [CrossRef]
  57. Li, Y.; Xiong, Z.; Yn, W.; Gao, E.; Cheng, H.; Wu, G.; Liu, Y.; Zhang, L.; Li, C.; Wang, S.; et al. Branched chain amino acids exacerbate myocardial ischemia/reperfusion vulnerability via enhancing GCN2/ATF6/PPAR-α pathway-dependent fatty acid oxidation. Theranostics 2020, 10, 5623–5640. [Google Scholar] [CrossRef]
Cimb 47 00325 g001
Figure 1. Effect of BCAAs on cancer cachexia. (A) An experimental protocol. Mice were divided into 3 groups; NoCa group (fed with CE-2 standard diet, no tumor), CD group (CE-2 diet, CT26 cells ip), and BCAA group (BCAA diet [Table 2], CT26 cells ip). Each group comprised 5 mice. (B) Dietary intake. (C) Body weight. (D) Tumor weight. Error bar, standard deviation from 5 mice. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. ANOVA, analysis of variance; BCAA, branched-chain amino acid; CD, control diet; No Ca, no cancer; ip, intraperitoneal inoculation.
Figure 1. Effect of BCAAs on cancer cachexia. (A) An experimental protocol. Mice were divided into 3 groups; NoCa group (fed with CE-2 standard diet, no tumor), CD group (CE-2 diet, CT26 cells ip), and BCAA group (BCAA diet [Table 2], CT26 cells ip). Each group comprised 5 mice. (B) Dietary intake. (C) Body weight. (D) Tumor weight. Error bar, standard deviation from 5 mice. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. ANOVA, analysis of variance; BCAA, branched-chain amino acid; CD, control diet; No Ca, no cancer; ip, intraperitoneal inoculation.
Cimb 47 00325 g001
Cimb 47 00325 g002
Figure 2. Effect of BCAAs on cancer sarcopenia. (A) QCM weight. (B) Muscle maturity by SDS-MYL1. (C) Muscle oxidative stress by 4HNE. (D) Muscle redox by GSH/GSSG ratio. (E,F) Muscle cytokines; TNFα (E) and HMGB1 (F). Error bar, standard deviation from 5 mice. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. 4HNE, 4-hydroxynonenal; ANOVA, analysis of variance; BCAA, branched-chain amino acid; CD, control diet; GSH, glutathione; GSSG, glutathione disulfide; HMGB1, high-mobility group box-1; NoCa, no cancer; QCM, quadriceps muscle; SDS-MYL1, SDS-soluble myosin light chain-1; TNF, tumor necrosis factor.
Figure 2. Effect of BCAAs on cancer sarcopenia. (A) QCM weight. (B) Muscle maturity by SDS-MYL1. (C) Muscle oxidative stress by 4HNE. (D) Muscle redox by GSH/GSSG ratio. (E,F) Muscle cytokines; TNFα (E) and HMGB1 (F). Error bar, standard deviation from 5 mice. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. 4HNE, 4-hydroxynonenal; ANOVA, analysis of variance; BCAA, branched-chain amino acid; CD, control diet; GSH, glutathione; GSSG, glutathione disulfide; HMGB1, high-mobility group box-1; NoCa, no cancer; QCM, quadriceps muscle; SDS-MYL1, SDS-soluble myosin light chain-1; TNF, tumor necrosis factor.
Cimb 47 00325 g002
Cimb 47 00325 g003
Figure 3. Effect of BCAAs on energy metabolism in an in vitro cachexia model. C2C12 cells (1 × 104) cells were pretreated with cancer ascites (20% v/v) to fresh DMEM medium. Then, cells were cultured in the mitochondrial stress test medium for 6 h. (A) Oxidative phosphorylation by flux analysis. (B) Basal respiration. (C) Maximum respiration. (D) ATP production. (E) Proton leak. (F) Spare respiration capacity. (G) ECAR. (H) Maximum ECAR. Error bar, standard deviation from 3 independent trials. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. ANOVA, analysis of variance; Asc, cancer ascites; ATP, adenosine triphosphate; BCAA, branched-chain amino acid; C, control; DMEM, Dulbecco’s Modified Eagle’s Medium; ECAR, Glycolysis by extracellular acidity rate; OCR, oxygen consumption rates.
Figure 3. Effect of BCAAs on energy metabolism in an in vitro cachexia model. C2C12 cells (1 × 104) cells were pretreated with cancer ascites (20% v/v) to fresh DMEM medium. Then, cells were cultured in the mitochondrial stress test medium for 6 h. (A) Oxidative phosphorylation by flux analysis. (B) Basal respiration. (C) Maximum respiration. (D) ATP production. (E) Proton leak. (F) Spare respiration capacity. (G) ECAR. (H) Maximum ECAR. Error bar, standard deviation from 3 independent trials. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. ANOVA, analysis of variance; Asc, cancer ascites; ATP, adenosine triphosphate; BCAA, branched-chain amino acid; C, control; DMEM, Dulbecco’s Modified Eagle’s Medium; ECAR, Glycolysis by extracellular acidity rate; OCR, oxygen consumption rates.
Cimb 47 00325 g003
Cimb 47 00325 g004
Figure 4. Impaired BCAA metabolism in an in vitro cachexia model. (A–C) C2C12 cells (1 × 106) were treated with cancer ascites (20% v/v to fresh DMEM medium) with or without BCAAs (Leu, Ile, and Val, 200 μM each) for 48 h. (A) Levels of BCAA metabolism-associated proteins. Right panel: semi-quantification of Western blotting. (B) Intramuscular BCAA concentration. (C) Intramuscular AcCoA concentration. (D–H) C2C12 cells were treated with HMGB1 (40 μg/mL) with or without BCAAs (Leu, Ile, and Val, 200 μM each) or C8 (50 μg/mL) for 48 h. (D) Expression of BCKD-related genes. Right panel: semi-quantification of RT-PCR. (E,F) Effect of HMGB1 on intramuscular BCAA (E) and AcCoA (F) concentrations. (G,H) Effect of C8 on intramuscular BCAA (G) and AcCoA (H) concentrations. Error bar: standard deviation from 3 independent trials. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. AcCoA, acetyl coenzyme A; ACTB, β-actine; ANOVA, analysis of variance; Asc, cancer ascites; BCAA, branched-chain amino acid; BDK, branched-chain ketoacid dehydrogenase kinase; BCKD, branched-chain α-ketoacid dehydrogenase; C8, caprylic acid; Cont, control; C, control; DMEM, Dulbecco’s Modified Eagle’s Medium; HMGB1, high-mobility group box-1; pBCKD, phosphorylated; PGC1A, peroxisome proliferator-activated receptor-γ coactivator-1α; RT-PCR, reverse transcription—polymerase chain reaction.
Figure 4. Impaired BCAA metabolism in an in vitro cachexia model. (A–C) C2C12 cells (1 × 106) were treated with cancer ascites (20% v/v to fresh DMEM medium) with or without BCAAs (Leu, Ile, and Val, 200 μM each) for 48 h. (A) Levels of BCAA metabolism-associated proteins. Right panel: semi-quantification of Western blotting. (B) Intramuscular BCAA concentration. (C) Intramuscular AcCoA concentration. (D–H) C2C12 cells were treated with HMGB1 (40 μg/mL) with or without BCAAs (Leu, Ile, and Val, 200 μM each) or C8 (50 μg/mL) for 48 h. (D) Expression of BCKD-related genes. Right panel: semi-quantification of RT-PCR. (E,F) Effect of HMGB1 on intramuscular BCAA (E) and AcCoA (F) concentrations. (G,H) Effect of C8 on intramuscular BCAA (G) and AcCoA (H) concentrations. Error bar: standard deviation from 3 independent trials. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. AcCoA, acetyl coenzyme A; ACTB, β-actine; ANOVA, analysis of variance; Asc, cancer ascites; BCAA, branched-chain amino acid; BDK, branched-chain ketoacid dehydrogenase kinase; BCKD, branched-chain α-ketoacid dehydrogenase; C8, caprylic acid; Cont, control; C, control; DMEM, Dulbecco’s Modified Eagle’s Medium; HMGB1, high-mobility group box-1; pBCKD, phosphorylated; PGC1A, peroxisome proliferator-activated receptor-γ coactivator-1α; RT-PCR, reverse transcription—polymerase chain reaction.
Cimb 47 00325 g004
Cimb 47 00325 g005
Figure 5. Effect of BCAAs combined with HMGB1 and/or C8 on energy metabolism in C2C12 cells. C2C12 cells were treated with BCAAs (Leu, Ile, and Val, 200 μM each), HMGB1 (40 μg/mL), and/or C8 (50 μg/mL) for 48 h. For flux assay, cells were then cultured in the mitochondrial stress test medium for 6 h. (A) Oxidative phosphorylation by flux analysis. (B) Basal respiration. (C) Maximum respiration. (D) ATP production. (E) Proton leak. (F) Maximum ECAR. (G) SDS-MYL1. (H) 4HNE. Error bar: standard deviation from 3 independent trials. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. 4HNE, 4-hydroxynonenal; ANOVA, analysis of variance; ATP, adenosine triphosphate; BCAA, branched-chain amino acid; C, control; C8, caprylic acid; ECAR, extracellular acidity rate; HMGB; HMGB1, high-mobility group box-1; OCR, oxygen consumption rates; SDS-MYL1, SDS-soluble myosin light chain-1.
Figure 5. Effect of BCAAs combined with HMGB1 and/or C8 on energy metabolism in C2C12 cells. C2C12 cells were treated with BCAAs (Leu, Ile, and Val, 200 μM each), HMGB1 (40 μg/mL), and/or C8 (50 μg/mL) for 48 h. For flux assay, cells were then cultured in the mitochondrial stress test medium for 6 h. (A) Oxidative phosphorylation by flux analysis. (B) Basal respiration. (C) Maximum respiration. (D) ATP production. (E) Proton leak. (F) Maximum ECAR. (G) SDS-MYL1. (H) 4HNE. Error bar: standard deviation from 3 independent trials. Statistical differences were calculated by ordinary ANOVA with Bonferroni’s correction. 4HNE, 4-hydroxynonenal; ANOVA, analysis of variance; ATP, adenosine triphosphate; BCAA, branched-chain amino acid; C, control; C8, caprylic acid; ECAR, extracellular acidity rate; HMGB; HMGB1, high-mobility group box-1; OCR, oxygen consumption rates; SDS-MYL1, SDS-soluble myosin light chain-1.
Cimb 47 00325 g005
Cimb 47 00325 g006
Figure 6. Effect of BCAAs on cancer sarcopenia in 5FU-administered mice. (A) An experimental protocol. Mice were divided into 5 groups: no cancer group (fed CE-2 standard diet, no tumor), CD group (fed BCAA diet [Table 2], CT26 cells ip), BCAA group (fed BCAA diet [Table 2], CT26 cells ip), BCAA + 5FU group (fed BCAA diet [Table 2], 5FU [30 mg/kg/w sc], CT26 cells ip) and BCAA + 5FU + C8 group (fed BCAA + C8 diet [Table 2], 5FU [30 mg/kg/w sc], CT26 cells ip). Each group comprised 5 mice. (B) Body weight. (C) Tumor weight. (D) QCM weight. (E) Muscle maturity by SDS-MYL1. (F) Muscle oxidative stress by 4HNE. Error bar: ordinary deviation from 5 mice. Statistical differences were calculated by standard ANOVA with Bonferroni’s correction. 4HNE, 4-hydroxynonenal; 5FU, 5-fluorouracil; ANOVA, analysis of variance; BCAA, branched-chain amino acid; C8, caprylic acid; CD, control diet (CE-2); QCM, quadriceps muscle; SDS-MYL1, SDS-soluble myosin light chain-1.
Figure 6. Effect of BCAAs on cancer sarcopenia in 5FU-administered mice. (A) An experimental protocol. Mice were divided into 5 groups: no cancer group (fed CE-2 standard diet, no tumor), CD group (fed BCAA diet [Table 2], CT26 cells ip), BCAA group (fed BCAA diet [Table 2], CT26 cells ip), BCAA + 5FU group (fed BCAA diet [Table 2], 5FU [30 mg/kg/w sc], CT26 cells ip) and BCAA + 5FU + C8 group (fed BCAA + C8 diet [Table 2], 5FU [30 mg/kg/w sc], CT26 cells ip). Each group comprised 5 mice. (B) Body weight. (C) Tumor weight. (D) QCM weight. (E) Muscle maturity by SDS-MYL1. (F) Muscle oxidative stress by 4HNE. Error bar: ordinary deviation from 5 mice. Statistical differences were calculated by standard ANOVA with Bonferroni’s correction. 4HNE, 4-hydroxynonenal; 5FU, 5-fluorouracil; ANOVA, analysis of variance; BCAA, branched-chain amino acid; C8, caprylic acid; CD, control diet (CE-2); QCM, quadriceps muscle; SDS-MYL1, SDS-soluble myosin light chain-1.
Cimb 47 00325 g006
Table 1. Components of media for treatment.
Table 1. Components of media for treatment.
ComponentMedium
D-MEMAscites Added 1)CM Added 2)
Glucose (mg/dL)450 ± 2361 ± 8378 ± 6
Pyruvate (mg/dL)11 ± 0.19 ± 19 ± 1
Glutamine (mg/dL)58 ± 0.249 ± 450 ± 3
Lactate (pmol)07.4 ± 1.41.2 ± 0.2
HMGB1 (μg/mL)ND18 ± 0.9ND
TNFα (pg/mL)ND12 ± 0.2ND
1) Ascites was collected from mice 2 weeks after inoculation of CT26 mouse colon cancer cells (1 × 107) intraperitoneally. Ascites was added at 20% v/v to fresh D-MEM culture medium supplemented with 10% FBS. 2) Cultured medium (CM) of CT26 cells (1 × 108) after 48 h was added at 20% v/v to fresh D-MEM culture medium supplemented with 10% FBS. D-MEM, Dulbecco’s Modified Eagle’s Medium; HMGB1, high-mobility group box-1; TNFα, tumor necrosis factor-α; ND, not detected.
Table 2. Food ingredients.
Table 2. Food ingredients.
IngredientControl DietBCAA DietBCAA + C8 Diet
Moisture (%)8.838.578.66
Crude protein (%)25.1324.3824.65
Crude fat (%)4.924.774.65
Crude fiber (%)4.424.284.21
Crude ash (%)6.866.656.54
NFE (%)49.8448.3447.35
Valine (%)-11
Laucine (%)-11
Isoleucine (%)-11
Energy (kcal)334.2345.874371.85
C8, caprylic acid; BCAA, branched-chain amino acid.
Table 3. Primary sets, antibodies, and enzyme-linked immunosorbent assay (ELISA) kits.
Table 3. Primary sets, antibodies, and enzyme-linked immunosorbent assay (ELISA) kits.
GeneAccession No.Upper PrimerLower Primer
PGC1ABC156323.1aaggatgcgctctcgttcaattcgtttgacctgcgcaaag
BDKCR542093.1ctcggtacctgcagcaagaatggcatagggatgaagggga
ACTBNM_007393.5acaatgagctgcgtgtggccagggacagcacagcctggat
TargetCat. No.CompanyAdderess
Antibodies
BCKDab126173AbcamCambridge, MA, USA
phospho-BCKD, pS293ab200577AbcamCambridge, MA, USA
BDKab128935AbcamCambridge, MA, USA
β-Actinsc-47778Santa-CruzDallas, TX, USA
ELISA kit
MYL1CSB-EL015305MOCusabio BiotechHouston, TX, USA
HMGB1326078738Shino TestSagamihara, Japan
Mouse TNF-αMTA00BR&D SystemsMinneapolis, MN, USA
GSH/GSSGCB-P050-KCreative BiolabsShirley, NY, USA
4HNESTA-838Cell Biolabs San Diego, CA, USA
BCAAMET-5056Cell Biolabs San Diego, CA, USA
AcCoARE10014Reed BiotechWuhan, China
4HNE, 4-hydroxynonenal; AcCoA, acetyl coenzyme A; BCAA, branched-chain amino acid; BCKD, branched-chain alpha-keto acid dehydrogenase α subunit; BDK, BCKD kinase; GSH, glutathione; GSSG, glutathione disulfide; HMGB1, high-mobility group box-1; MYL1, myosin light chain-1; TNF, tumor necrosis factor.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kawahara, I.; Fujiwara-Tani, R.; Mori, T.; Nukaga, S.; Nishida, R.; Miyagawa, Y.; Goto, K.; Ohmori, H.; Fujii, K.; Luo, Y.; et al. Caprylic Acid Restores Branched-Chain Amino Acid Metabolism in a Mouse Cachexia Model. Curr. Issues Mol. Biol. 2025, 47, 325. https://doi.org/10.3390/cimb47050325

AMA Style

Kawahara I, Fujiwara-Tani R, Mori T, Nukaga S, Nishida R, Miyagawa Y, Goto K, Ohmori H, Fujii K, Luo Y, et al. Caprylic Acid Restores Branched-Chain Amino Acid Metabolism in a Mouse Cachexia Model. Current Issues in Molecular Biology. 2025; 47(5):325. https://doi.org/10.3390/cimb47050325

Chicago/Turabian Style

Kawahara, Isao, Rina Fujiwara-Tani, Takuya Mori, Shota Nukaga, Ryoichi Nishida, Yoshihiro Miyagawa, Kei Goto, Hitoshi Ohmori, Kiyomu Fujii, Yi Luo, and et al. 2025. "Caprylic Acid Restores Branched-Chain Amino Acid Metabolism in a Mouse Cachexia Model" Current Issues in Molecular Biology 47, no. 5: 325. https://doi.org/10.3390/cimb47050325

APA Style

Kawahara, I., Fujiwara-Tani, R., Mori, T., Nukaga, S., Nishida, R., Miyagawa, Y., Goto, K., Ohmori, H., Fujii, K., Luo, Y., Sasaki, T., Nakashima, C., Ogata, R., & Kuniyasu, H. (2025). Caprylic Acid Restores Branched-Chain Amino Acid Metabolism in a Mouse Cachexia Model. Current Issues in Molecular Biology, 47(5), 325. https://doi.org/10.3390/cimb47050325

Article Metrics

Back to TopTop